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Linear ubiquitin (Ub) plays a role in nuclear factor kB signaling, but the deubiquitinating enzyme that
disassembles these chains was unknown. In this issue of Cell, Keusekotten et al. identify a new
enzyme that disassembles linear chains with the use of a mechanism that relies on Ub itself to
help catalyze peptide bond cleavage.Ubiquitination plays a remarkable range
of signaling roles in diverse cellular pro-
cesses, including protein degradation,
the DNA damage response, kinase acti-
vation, and the inflammatory response
(Komander and Rape, 2012). The ubiqui-
tin (Ub) modification can consist of a sin-
gle Ub protein (monoubiquitination) or
one of a variety of polyubiquitin (polyUb)
chains, each signaling a distinct outcome.
The Ub C terminus is covalently linked to
substrate lysines in the E1-E2-E3 enzyme
cascade, yielding an isopeptide bondwith
the epsilon amine of lysine. Ub itself can
be ubiquitinated at any of its seven
lysines, resulting in different types of
polyUb chains. Adding to this complexity
was the discovery of Met1-linked linear
polyUb chains that are assembled by
peptide bond formation between the
C terminus of one Ub and the N terminusof the next (reviewed in Rieser et al.,
2013). The most well-characterized role
of linear Ub is in TNFa signaling, where
these polyUb chains are instrumental in
activating the inhibitor of kB kinase (IKK)
complex and, ultimately, lead to the trans-
location of nuclear factor kB (NF-kB)
to the nucleus (Tokunaga et al., 2009). A
key question in studies of linear polyUb
signaling is how this unique chain type is
assembled and degraded. Only one E3
ligase complex, linear Ub chain assembly
complex (LUBAC), is known to assemble
linear Ub (Kirisako et al., 2006), whereas
the identity of the deubiquitinating
enzyme that specifically cleaves linear
Ub remained unknown. In this issue of
Cell, Keusekotten et al. (2013) identify
a deubiquitinating enzyme (DUB) that
they name OTULIN (ovarian tumor [OTU]
DUB with linear linkage specificity)that cleaves linear Ub and antagonizes
LUBAC, thereby regulating NF-kB sig-
naling (Figure 1A).
Although upwards of 90 DUBs have
been identified in the human genome
(Komander et al., 2009), the enzyme that
cleaves linear Ub turned out to be a
previously unannotated protein called
Fam105b. Keusekotten et al. (2013)
used a bioinformatics screen to identify
Fam105b as a putative member of the
OTU family of DUBs with an intact cata-
lytic triad of Cys, His and Asn. However,
in contrast to the 14 known OTU family
members, they found that FAM105b/
OTULIN is unable to cleave isopeptide
linkages. Instead, OTULIN is a peptidase
that exclusively cleaves Met1-linear Ub.
A particular surprise is that OTULIN
does not cleave Lys63-linked polyUb,
despite the similarity between linear and53, June 6, 2013 ª2013 Elsevier Inc. 1189
Figure 1. OTULIN Acts as the DUB for Linear
Ubiquitin Chains
(A) The E3 ligase complex LUBAC assembles linear
Ub by forming peptide bonds between the N and
C termini of successive Ub monomers. These
peptide bonds are cleaved by OTULIN, which
disassembles linear polyUb chains and releases
monomeric Ub.
(B) OTULIN binds to diUb, positioning the peptide
bond that joins Met1 of the proximal Ub with the
C-terminal Gly76 of the distal Ub in the OTULIN
active site. Glu16 (E16) of the proximal Ub inserts
into the active site and helps to position the
catalytic triad for catalysis.
(C) OTULIN antagonizes LUBAC signaling. Linear
Ub chains are involved in TNFa signaling, down-
stream activation of MAPK, and the translocation
of NF-kB to the nucleus.K63-linked polyUb chains that arises
because K63 is immediately adjacent to
Met1. High-resolution crystal structures
of OTULINwith andwithout a bound linear
diubiquitin (diUb) substrate (Keusekotten
et al., 2013) show OTULIN to be remark-
ably similar in fold to OTUB1, another
OTU DUB that specifically cleaves K48-
linked polyUb. Like OTUB1 (Juang et al.,
2012; Wiener et al., 2012), OTULIN
contains distinct binding sites for the
proximal and distal Ubs (Figure 1B). Given
these similarities, how is it that OTULIN1190 Cell 153, June 6, 2013 ª2013 Elsevier Inis so specific for the Met1 peptide bond
and, yet, unable to cleave other types
of polyUb chains containing isopeptide
linkages?
It turns out that OTULIN not only favors
binding to peptide-linked linear Ub but
also relies upon the Ub substrate to be
a party to its own destruction. The
OTULIN-binding sites are uniquely
tailored to accommodate linear Ub,
which binds 100-fold more tightly to OTU-
LIN than even structurally similar K63-
linked chains. OTULIN orients the linear
diUb substrate with the amino terminus
of the proximal Ub (Figure 1B) in the active
site and prevents access by other Ub ly-
sines, further enforcing specificity for
linear Ub. Importantly, this orientation en-
ables Glu16 of the proximal Ub to
contribute directly to enzyme catalysis
by positioning residues in the catalytic
triad in a catalytically competent state, a
mechanism known as substrate-assisted
catalysis. The reliance of OTULIN on
both selective binding to linear chains
and substrate-assisted catalysis is
exploited to ensure that OTULIN disas-
sembles only linear Ub, whose abun-
dance in the cell is low in relation to iso-
peptide-linked polyUb chains. This is
the first example of a deubiquitinating
enzyme that relies upon substrate-
assisted catalysis. Given that the present
study marks only the second structure of
a DUB bound to a true substrate, it will
be interesting to see whether substrate-
assisted catalysis is used by other DUBs
to ensure substrate specificity or whether
deubiquitinating enzyme activators may
also exploit this mechanism for their func-
tion.
OTULIN antagonizes linear Ub sig-
naling in the cell (Figure 1C), consistent
with a role in disassembling this unique
chain type. Although the cellular roles
of linear Ub are still under active study,
its role has been best characterized in
NF-kB signaling. Expression of LUBAC,
the multisubunit E3 ligase that assembles
Met1-linked polyUb chains, induces
NF-kB signaling (Tokunaga et al., 2009).
Accordingly, the expression of wild-type
OTULIN, but not a catalytic mutant,
decreases levels of linear Ub. However,
the expression of catalytically inactive
OTULIN also inhibits NF-kB signaling,
suggesting an additional noncatalytic
role for OTULIN. Keusekotten et al.c.(2013) suggest that catalytically inactive
OTULIN serves as a trap for linear Ub
and thereby competes with linear
Ub-binding proteins required for NF-kB
signaling. Whether the effect of catalyti-
cally inactive OTULIN reflects an addi-
tional noncatalytic role in regulating
Met1-Ub chain assembly, analogous to
the ability of the related OTUB1 enzyme
to inhibit K63-linked polyubiquitination
by binding to E2 Ub-conjugating en-
zymes, remains an open question (Na-
kada et al., 2010; Wiener et al., 2012).
Many deubiquitinating enzymes have
been found in complex with Ub E3 ligases
(Sowa et al., 2009), an unexpected find-
ing given their opposing activities. This
feature is apparently shared by OTULIN,
which can be coprecipitated with LUBAC
(Keusekotten et al., 2013). The benefit of
coupling chain assembly and disas-
sembly is still not known, but it suggests
crosstalk between these two classes of
enzymes. OTULIN removes linear Ub
from LUBAC, leaving open the possibility
that this may provide a mechanism for
regulating E3 activity. Whether this is,
indeed, important for LUBAC E3 activity
or whether LUBAC affects OTULIN deubi-
quitinating activity are both questions
that need to be resolved. Putting aside
whether one activity affects the other, it
is possible that the nature of this coupling
is to ensure rapid disassembly of un-
wanted polyUb chains by tethering the
deubiquitinating enzyme close to the
chain assembly machinery.
The ability of ubiquitination to regulate
so many different cellular processes is
ascribed to its ability to form a large
spectrum of modifications, ranging from
monoubiquitin to polyUb chains, with
different linkages. Having enzymes that
disassemble specific types of chains has
been useful in uncovering the role of
particular types of Ub modifications. The
discovery of an enzyme, OTULIN, that
specifically disassembles linear chains
not only advances our mechanistic
understanding of linear Ub processing
but also provides an invaluable tool for
investigating the functions of this unique
type of polyUb chain.REFERENCES
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A clinically efficacious Ras inhibitor has eluded drug-discovery efforts for decades. In a paper in
Nature, Zimmermann and et al. show that blocking a hole in PDEd that normally engages the lipid
tail of Ras disrupts downstream signaling, pointing to a potentially promising route to develop Ras
inhibitors for cancer treatment.Activating Ras mutations are found very
frequently in human cancers (Schubbert
et al., 2007). In particular, mutations in
the K-Ras isoform are prevalent in cer-
vical, lung, pancreatic, and colorectal
cancers and are associated with a poor
prognosis. Unfortunately, no clinically
viable drugs have yet been developed to
inhibit Ras signaling directly. Ras binds
to guanosine diphosphate and guanosine
triphosphate (GTP) with picomolar affin-
ity, making it challenging to develop
competitive inhibitors for the nucleotide-
binding pocket, given the abundance of
free nucleotides in the cell. An intense
effort to block Rasmaturation by targeting
Ras farnesyl transferases appears to have
stalled. Given the demand for small mole-
cule inhibitors that target Ras signaling,
investigators have been searching for
alternative approaches to achieve this
end. In a recent issue of Nature, Zimmer-
mann et al. (2013) report exciting newfindings on the inhibition of Ras signaling
by targeting the Ras-binding protein
PDEd, which has a deep pocket that ap-
pears most welcoming to small molecules
(Zimmermann et al., 2013).
Ras activity arises from the combined
actions of guanine nucleotide exchange
factors, which cause the release of bound
nucleotide and subsequent binding of
GTP, and GTPase activating proteins
(GAPs) that accelerate hydrolysis of Ras-
bound GTP (Cherfils and Zeghouf, 2013).
Oncogenic Ras mutations subvert GAP-
induced GTP hydrolysis, leading to
constitutive signaling. An additional level
of regulation is made possible by the
fact that lipid modifications at the C termi-
nus of Ras-family proteins are necessary
for function. These lipid anchors control
the final destination within the cell of
different Ras isoforms and limit the free
diffusion of the proteins through the cyto-
plasm. PDEd controls the intracellularlocalization of Ras-like proteins by bind-
ing to their farnesyl tails (Figure 1). In this
way, PDEd enhances the cytoplasmic
diffusion of Ras, allowing it to distribute
to the proper subcellular compartments
where signaling is initiated (Chandra
et al., 2012; Nancy et al., 2002).
PDEd was discovered originally as a
subunit of phosphodiesterase 6 (PDE6)
in photoreceptor cells, where it likely
plays a role in binding to the lipid tails of
the PDE6 catalytic subunits. The farnesyl
anchor at the C terminus of Ras and other
proteins is recognized by a hydrophobic
hole in the immunoglobulin-like b sand-
wich fold of PDEd (Ismail et al., 2011).
The action of PDEd is similar to that of
Rho guanine nucleotide dissociation in-
hibitors (GDIs) (Hanzal-Bayer et al.,
2002), which also use a b sandwich fold
to recognize the geranylgeranyl moiety
of the Rho GTPase. RhoGDIs employ a
second domain to contact the switch I53, June 6, 2013 ª2013 Elsevier Inc. 1191
